Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain MDXG message board posts where the ticker symbol MDXG has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest MDXG SEC Filings

Filings Format Description Filing Date File/Film Number
SC 13D/A  Documents [Amend] General statement of acquisition of beneficial ownership
Acc-no: 0001144204-18-053048 (34 Act)  Size: 51 KB
2018-10-10 005-83552
8-K  Documents Current report, items 5.03 and 9.01
Acc-no: 0001193125-18-293374 (34 Act)  Size: 160 KB
2018-10-04 001-35887
8-K  Documents Current report, items 7.01 and 9.01
Acc-no: 0001193125-18-278910 (34 Act)  Size: 32 KB
2018-09-21 001-35887
8-K  Documents Current report, items 5.02, 7.01, and 9.01
Acc-no: 0001193125-18-278879 (34 Act)  Size: 37 KB
2018-09-20 001-35887
8-K  Documents Current report, item 1.02
Acc-no: 0001193125-18-265093 (34 Act)  Size: 16 KB
2018-08-31 001-35887
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB
Acc-no: 0001193125-18-247342 (34 Act)  Size: 21 KB
2018-08-13 001-35887
8-K  Documents Current report, items 7.01 and 9.01
Acc-no: 0001193125-18-227970 (34 Act)  Size: 27 KB
2018-07-26 001-35887
8-K/A  Documents [Amend] Current report, items 5.02 and 9.01
Acc-no: 0001193125-18-215806 (34 Act)  Size: 129 KB
2018-07-11 001-35887
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001376339-18-000046 Size: 12 KB
8-K  Documents Current report, items 5.02, 7.01, and 9.01
Acc-no: 0001193125-18-210478 (34 Act)  Size: 42 KB
2018-07-02 001-35887
More MDXG SEC Filings

Related news from
Wed, 10 Oct 2018
11:28:41 +0000
MiMedx founder and former CEO Pete Petit prepares for battle
Three and a half months after exiting the Atlanta-based biomedical company he founded, MiMedx Group Inc., Pete Petit is preparing for battle. Several other former top MiMedx execs have also left the company. On Sept. 21, MiMedx said it would seek to recover compensation previously paid to four senior MiMedx executives, including Petit.
Mon, 08 Oct 2018
00:13:06 +0000
[$$] MiMedx Kept Cheaper Products Out of Its Offerings to VA Hospitals
The MiMedx Group, a maker of amniotic-tissue products, is a major supplier to government-run hospitals and says its products help heal wounded service members and veterans. According to former employees and company product lists, MiMedx limited the range of products it offered to federal buyers, forcing the government to buy more expensive products than it needed for some very common treatments. The company, based in Marietta, Ga., manufactures skin grafts and injectable products from donated placental tissues.
Fri, 05 Oct 2018
00:48:00 +0000
Here's Why MiMedx Group, Inc. Gained 16.6% in September
A C-suite sweep and good news from a major market exchange lifted the troubled biotech stock.
Tue, 25 Sep 2018
17:11:01 +0000
How to Identify a Perfect Short Target
After all, institutions, mutual funds and their ilk have bureaucratic controls, and clients who can get nervous about a strategy that goes against the grain. Warning! GuruFocus has detected 1 Warning Sign with PVG. One of the greats of the modern short game is Marc Cohodes.
Tue, 25 Sep 2018
12:30:00 +0000
MiMedx Publishes Positive Results From Clinical Study Of Human Umbilical Cord For Diabetic Foot Ulcers
Study Published in International Wound Journal Reported Statistically Significant Evidence of Healing Compared to Standardized Therapy (ST) - Intent-To-Treat (ITT) EpiCord®-Treated Patients = 70% vs ST ...
Fri, 21 Sep 2018
19:36:53 +0000
MiMedx Stock Shoots Higher After Earlier Drop
MiMedx (NASDAQ:MDXG) had a mixed day on Friday that ultimately resulted in a surge as the company is seeking to ameliorate some of its past transgressions. The stock had suffered from the internal probe, which looked into MiMedx’s sales and distribution practices, leading to the indictment of three people who were employed by the Department of Veteran Affairs.
Fri, 21 Sep 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: MiMedx Group and Galectin Therapeutics
NEW YORK, NY / ACCESSWIRE / September 21, 2018 / Wall Street closed up on Thursday as upbeat economic data and strong corporate earnings helped buoy equities. Unemployment dropped by 3000 to a seasonally ...
Fri, 21 Sep 2018
02:00:00 +0000
Kaskela Law LLC Announces Investigation of MiMedx Group, Inc. on Behalf of Current Stockholders - MDXG
RADNOR, PA / ACCESSWIRE / September 20, 2018 / Kaskela Law LLC is investigating MiMedx Group, Inc. (NASDAQ: MDXG) ("MiMedx" or the "Company") on behalf of the Company's current stockholders. ...
Fri, 21 Sep 2018
00:30:57 +0000
[$$] Former MiMedx Executives to Lose Compensation
The findings announced Thursday were part of an investigation launched by the board’s audit committee earlier in 2018. The investigation is ongoing, the troubled tissue-graft developer said Thursday, adding that other actions might be taken.
Thu, 20 Sep 2018
21:51:36 +0000
MiMedx Ex-CEO Criticizes ‘Unfair’ Probe That Led to His Ouster
Hours after MiMedx Group Inc. said it will claw back compensation from four former top managers for harming the company, two of those affected criticized the investigation that led to their resignations earlier this year. Ex-Chief Executive Officer Parker H. Petit and Bill Taylor, who was chief operating officer, are both victims of a company trying to clear itself of accusations of alleged malfeasance by dismissing senior bosses, a lawyer representing the two men said in a statement. The biotech firm, which is under investigation by the Justice Department and the Securities and Exchange Commission, said Thursday it will recoup compensation from Petit, Taylor and ex-finance chiefs Michael Senken and John Cranston.
Thu, 20 Sep 2018
21:15:00 +0000
MiMedx Announces Nasdaq Listing Extension
MARIETTA, Ga. , Sept. 20, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that a Nasdaq Hearings Panel ...
Thu, 20 Sep 2018
21:10:00 +0000
Mimedx Provides Update on Previously Announced Senior Executive Separations
MARIETTA, Ga., Sept. 20, 2018 /PRNewswire/ -- The Board of Directors (the "Board") of MiMedx Group, Inc. (MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it has determined that the previously announced separations of four senior MiMedx executives – Parker H. Petit, William C. Taylor, Michael J. Senken, and John E. Cranston (collectively, the "Separated Employees") – be treated as terminations "for cause".
Mon, 10 Sep 2018
16:44:00 +0000
Here's Why MiMedx Group Inc. Rose 24.7% in August
The company announced product updates and earned an extension to remain listed on the Nasdaq exchange -- for now.
Fri, 24 Aug 2018
12:30:00 +0000
MiMedx Announces Statistically Significant Results In New Multicenter Clinical Study Of Healing Of Diabetic Foot Ulcers Using EpiFix®
- Study Published in International Wound Journal Reported Statistically Significant Evidence of Healing Compared to Control Group - Intent-To-Treat EpiFix Treated Patients = 70% vs Control 50%, p=0.0338 ...
Thu, 16 Aug 2018
20:33:00 +0000
Why Dillard's, MiMedx Group, and Global Net Lease Slumped Today
Find out which of these stocks fared the worst on an positive day for the market.
Thu, 16 Aug 2018
02:47:07 +0000
[$$] Health Insurer Shuns Amniotic-Tissue Product From MiMedx
United Healthcare, one of the nation’s largest insurance companies, has determined that amniotic tissue products made by MiMedx Group Inc. and other manufacturers are “unproven and/or not medically necessary for any indication,” and won’t reimburse patients for their use, according to the insurer’s most recent medical policy update bulletin. The updated policy at United Healthcare, which goes into effect Oct. 1, came about because of “insufficient clinical evidence of safety and/or efficacy in published peer-reviewed medical literature” about the products, the bulletin said. “Unlike many other insurers, UnitedHealthcare has not covered MiMedx products, so this does not represent a change in coverage,” said a MiMedx spokesman.
Wed, 15 Aug 2018
21:15:00 +0000
MiMedx Receives Additional Nasdaq Listing Notice Due to Late Form 10-Q
MARIETTA, Ga., Aug. 15, 2018 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it received written notification, as expected, from the Nasdaq Stock Market indicating that the Company's failure to timely file a Form 10-Q for the period ended June 30, 2018 could serve as an additional basis for delisting, and that the Company should be prepared to address the additional delinquency at its already scheduled hearing in September before a Nasdaq Hearings Panel (the "Panel"). Nasdaq previously notified the Company that it was not in compliance with Nasdaq Listing Rule 5250(c) due to the delay in the Company's filing of the Form 10-K for the year ended December 31, 2017 and Form 10-Q for the period ended March 31, 2018.
Wed, 15 Aug 2018
17:30:00 +0000
MiMedx Provides Additional Information and Context to Wall Street Journal Article
MiMedx products are manufactured according to current Good Tissue Practices (cGTP) standards, pursuant to the Food and Drug Administration ("FDA") regulations specified in 21 CFR 1271, which are the requirements and guidelines the Company must follow. MiMedx is also in compliance with the American Association of Tissue Banks' 14th standard, of which the Company is a fully accredited member in good standing. In addition, certain MiMedx products are marketed as cellular and tissue based products ("HCT/Ps") under Section 361 of the Public Health Service Act until either a biologics license application ("BLA") by the Company is approved or the FDA's enforcement discretion under the November 2017 guidance document1 ends.
Wed, 15 Aug 2018
00:42:51 +0000
[$$] Insurer Stops Reimbursing for Some MiMedx Products
The decision by Health Care Service Corp., effective Aug. 1, will likely curb the use of products promoted aggressively for an array of ailments including hair loss, erectile dysfunction, knee pain and osteoarthritis. The policy change, which hasn’t been publicly reported, was issued by the nation’s largest customer-owned health insurer, the parent of Blue Cross/Blue Shield operations covering 15 million members in Illinois, Montana, New Mexico, Oklahoma and Texas. The company said it won’t reimburse for injections of human amniotic fluid or “micronized or particulated human amniotic membrane,” such as MiMedx’s Amniofix products.

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has been the most valuable tool I have ever come across when it comes to managing my investments. I can honestly say that the information shared on ValueForum has led me to retire earlier than expected. This is a wonderful investment site, period." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards